Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance - Wang, Ling; Wang, Qi; Xu, Yangchun; Cui, Manhua; Han, Liying (Current drug targets, 2020)
Keywords: Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Benzimidazoles - therapeutic use; BRCA1 Protein - genetics; BRCA1 Protein - metabolism; BRCA2 Protein - genetics; BRCA2 Protein - metabolism; Carcinoma, Ovarian Epithelial - drug therapy; DNA Repair - drug effects; Drug Resistance, Neoplasm - drug effects; Female; Humans; Indazoles - therapeutic use; Indoles - therapeutic use; Neoplasm Recurrence, Local - drug therapy; Ovarian Neoplasms - drug therapy; Phthalazines - therapeutic use; Piperazines - therapeutic use; Piperidines - therapeutic use; Poly(ADP-ribose) Polymerase Inhibitors - adverse effects; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Poly(ADP-ribose) Polymerases - metabolism; toxicity; MeSH; drug resistance mechanism; ovarian cancer; PARP inhibitors; targeted treatment